AB0530 THE EFFECT OF MYCOPHENOLATE MOFETIL ON NON-RENAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM 2014 TO 2018: OBSERVATION STUDY FROM KOREAN LUPUS NETWORK (KORNET) REGISTRY

Abstract

Background: Mycophenolate mofetil (MMF) has been established to a potent therapeutic drug for regulate renal involvement in systemic lupus erythematosus (SLE). Objectives: The object of this study is to identify the effect of MMF on non-renal manifestations in SLE. Methods: The study population was total 439 SLE patients enrolled from Korean Lupus Network (KORNET) registry. The KORNET registry was followed up annually and completed from baseline survey to the 2nd visits from 2014 to 2018. In the subgroup analysis, the effect of MMF on clinical features was also evaluated in 110 patients with histologically confirmed lupus nephritis (LN). The changes of clinical features including mucocutaneous lesions, arthritis, serositis, neurologic disorder, and hematologic abnormalities were assessed between MMF and non-MMF groups during follow-up period. Statistical analysis was used by multiple comparison analysis, considering time, group, and interaction of follow-up time and treatment group. Results: There was significant difference of malar rash and renal disorder between MMF and non-MMF groups considering time and group in total SLE patients (p = 0.025 and p Conclusion: This study showed that MMF might be beneficial to treatment for hematologic abnormalities in SLE.